Publicaciones en colaboración con investigadores/as de Universidad Austral de Chile (32)

2024

  1. Environmental DNA reveals temporal variation in mesophotic reefs of the Humboldt upwelling ecosystems of central Chile: Toward a baseline for biodiversity monitoring of unexplored marine habitats

    Ecology and Evolution, Vol. 14, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Pharmacotherapy and clinical outcomes of hospitalized COVID-19 patients in Chile during the first wave of pandemic

    Revista Medica de Chile, Vol. 151, Núm. 5, pp. 541-550

2022

  1. A systematic evidence map of conservation knowledge in Chilean Patagonia

    Conservation Science and Practice, Vol. 4, Núm. 1

2020

  1. Exploring gaps in mapping marine ecosystem services: A benchmark analysis

    Ocean and Coastal Management, Vol. 192

2019

  1. Tanycytes: A rich morphological history to underpin future molecular and physiological investigations

    Journal of Neuroendocrinology, Vol. 31, Núm. 3

2017

  1. Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow

    Fluids and Barriers of the CNS, Vol. 14, Núm. 1

  2. Delphinidin reduces glucose uptake in mice jejunal tissue and human intestinal cells lines through FFA1/GPR40

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

2016

  1. A pharmacist's role in the individualization of treatment of HIV patients

    Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188

  2. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  3. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

2014

  1. Delphinidin Activates NFAT and Induces IL-2 Production Through SOCE in T Cells

    Cell Biochemistry and Biophysics, Vol. 68, Núm. 3, pp. 497-509

  2. Dose reduction of efavirenz: An observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics

    Pharmacogenomics, Vol. 15, Núm. 7, pp. 997-1006

  3. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

  2. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2011

  1. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  3. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

2010

  1. Cell organization of the rat pars tuberalis. Evidence for open communication between pars tuberalis cells, cerebrospinal fluid and tanycytes

    Cell and Tissue Research, Vol. 339, Núm. 2, pp. 359-381